Glenmark Lays Out US Flovent Plans, Discusses Growing Debt Pile
Welcomes ‘Strong Uptake’ For Ryaltris In EU, Reveals Further Filing Plans
Executive Summary
India’s Glenmark is hoping that its proposed generic version of GlaxoSmithKline’s Flovent will benefit from a limited competition market, as it continues to plan a filing with the US Food and Drug Administration.
You may also be interested in...
Glenmark Divests API Company, Setting Out On Distinct Journeys
Glenmark Pharmaceuticals has divested its API arm to the Nirma group for over $681m, a move that will deleverage the drug maker’s balance sheet as it seeks to evolve into an “innovative/brand led organization.”
Glenmark Divests API Company, Setting Out On Distinct Journeys
Glenmark Pharmaceuticals has divested its API arm to the Nirma group for over $681m, a move that will deleverage the drug maker’s balance sheet as it seeks to evolve into an “innovative/brand led organization.”
Glenmark Reaches Eight-Figure Settlement In US Zetia Antitrust Case
A five-year old case on the cusp of trial involving Glenmark, Merck and the originator’s Zetia has produced a settlement dealing defendants out of the claims – for one class of plaintiffs at least.